Understanding the impaired glucose tolerance phenotype is essential for effective diabetes prevention in clinical practice. While clinicians traditionally link impaired glucose tolerance (IGT) with insulin resistance, new evidence suggests a different pathway for some individuals. The STOP DIABETES trial reveals that a significant number of patients progress to IGT despite having normal total body insulin sensitivity (IS). This unique subgroup challenges the traditional view that metabolic dysfunction always begins with cellular resistance to insulin.

Metabolic Insights into the Impaired Glucose Tolerance Phenotype

Specifically, the researchers analyzed data from the STOP DIABETES trial to compare insulin-sensitive and insulin-resistant patients. The study identified two distinct groups based on the Matsuda index. They found that 107 subjects were insulin-sensitive yet still manifested IGT. Furthermore, these patients showed metabolic profiles that differed significantly from the 222 insulin-resistant subjects. Notably, the study also compared these individuals to healthy patients with normal glucose tolerance and specific 1-hour plasma glucose levels.

Consequently, identifying this specific phenotype helps doctors personalize treatment strategies for prediabetes. Because these patients maintain insulin sensitivity, their glucose intolerance may stem from early beta-cell dysfunction or specific defects in postprandial glucose handling. Therefore, relying solely on insulin resistance markers might miss these high-risk individuals. Additionally, the trial highlights the importance of the 1-hour glucose test as a vital diagnostic tool. In conclusion, clinicians should look beyond standard resistance metrics to capture the full spectrum of metabolic impairment.

Frequently Asked Questions

Can a patient have IGT without insulin resistance?

Yes, research from the STOP DIABETES trial shows that a subset of patients exhibits impaired glucose tolerance despite having normal insulin sensitivity, often due to underlying beta-cell limitations.

What did the trial discover about these insulin-sensitive patients?

The trial found that insulin-sensitive IGT patients have distinct metabolic features compared to insulin-resistant patients, suggesting they may require different therapeutic approaches to prevent progression.

Why is the 1-hour glucose test significant in this study?

The 1-hour plasma glucose level acts as an early indicator of dysglycemia, often identifying risk in patients who might otherwise appear normal on standard 2-hour or fasting tests.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

1. Armato J et al. Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization (STOP DIABETES). Diabetes Obes Metab. 2026 Apr 13. doi: 10.1111/dom.70762. PMID: 41969201.


2. Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018;6(10):781-789.


3. DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to preventing the progression from IGT to T2DM. Exp Clin Endocrinol Diabetes. 2011;119(4):183-193.